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1875-9572/Copyright ª 2014, TaiwanMenkes disease is a rare neurodegenerative disorder caused by mutations in ATP7A gene. Defi-
ciency in copper-dependent enzymes results in the unique kinky hair appearance, neurodegen-
eration, developmental delay, seizures, failure to thrive and other connective tissue or organ
abnormalities. Other than biochemical tests, DNA-based diagnosis is now playing an important
role. More than two hundred mutations in ATP7A gene were identified. Early copper supple-
mentation can help improve neurological symptoms, but not non-neurological problems.
Further molecular studies are needed to identify additional mutation types and to understand
the mechanism of pathogenesis. This may help in discovering the possible treatment measures
to cure the disease. We present a case with the clinical features and biochemical findings,
abnormal brain magnetic resonance imaging as well as the effects of treatment with
copper-histidine. Direct sequencing of ATP7A gene revealed a de novo point mutation which
resulted in an early stop codon with truncated protein.
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Menkes disease (MD; MIM# 309400) is a disorder of copper
metabolism caused by mutations in ATP7A gene. The clin-
ical manifestations are progressive neurologic deteriora-
tion, seizures, hair and connective tissue abnormalities.
Early diagnosis is difficult. Up-to-date, effective cure has
not been reported; however, early copper supplementation
can improve neurological outcomes.1 We demonstrate a
case whose gene sequencing revealed a de novo truncating
mutation.2. Case report
A four-month-old male infant was brought to our Pediatric
outpatient clinic because of seizure. The pattern of seizure
was head shaking with upward gaze, lasting for one minute
in each episode, and five to six episodes a day for two days.
The infant was delivered via cesarean section at 36 3/7
weeks’ gestation with birth weight of 2,620 gm at a local
obstetric clinic. The Apgar score was 9 and 10 at 1 and 5
minutes, respectively. The prenatal examination of the 37-
year-old G2P2 mother was normal. No other family mem-
bers had seizure history or hereditary disease. The results
of newborn screening tests were normal.
This was his fourth time of admission. Histories of
hyperbilirubinemia, bilateral inguinal hernias, pectus
excavatum, left side grade III vesicoureteral reflux, diffuse
multiple urinary bladder diverticula, and normocytic ane-
mia were documented in the previous three courses of
hospitalization.
On admission, physical examination revealed flat
occiput, flat face and depressed nasal bridge with bilateral
large floppy ears. The scalp hair was hypopigmented,
sparse, curly and brittle (Figure 1). The color of the iris was
normal. He had prominent funnel chest, cutis laxa and
loose joints. Deep tendon reflexes were increased with
hypotonia of four limbs. He failed in reaching the normal
developmental milestones, including social smile, head
control and rolling over.
Phenobarbital and valproic acid were prescribed and
seizure subsided after the 3rd day of hospitalization. InitialFigure 1 The scalp hair is hypopigmented, sparse, curly and
brittle.
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decreased resistance index. The electroencephalography
(EEG) showed epileptiform discharges over left temporal
and posterior area, with contralateral propagations. Brain
magnetic resonance imaging (MRI) disclosed encephaloma-
lacia in bilateral temporal and left frontal lobes
(Figure 2A,B). T2WI and T2 FLAIR sequence revealed sym-
metric faint hyperintense areas in bilateral head of caudate
nucleus and putamen (Figure 2C). T1WI sequence showed
faint hypointensity in the same areas. Dysgenesis of the
genu and anterior body of corpus callosum was also
observed (Figure 2D).
The lesions over basal ganglia provided a clue of po-
tential metabolic disorder. Another clue was the elevated
lactate-to-pyruvate ratio. The ratios checked initially and 2
days later were 21 and 24.6, respectively. A Geneticist was
then consulted for his physical anomalies and possible
metabolic disorder. Tests of plasma amino acids profile,
urine organic acids analysis, plasma carnitine levels, and
mitochondrial DNA sequencing showed normal results,
except for elevated lactic acid level in organic acids anal-
ysis. The serum concentrations of copper and ceruloplasmin
were 116 ppb (ref: 700e1500 ppb) and 5 mg/dL (ref:
20e60 mg/dL), both lower than the normal range. The
laboratory findings above, together with his clinical mani-
festations, made the diagnosis of Menkes kinky hair disease
highly suspicious. Molecular study then confirmed a point
mutation in ATP7A gene (c.3502 C>T) leading to an early
stop codon with truncated protein (p.Gln1168X). The
mother is not a carrier of the mutation. Treatment with
daily subcutaneous injections of copper-histidine was
started from the age of eight-months. On follow-up at
twelve months of age, MRI and magnetic resonance angi-
ography showed brain atrophy (Figure 3A), and tortuosity of
bilateral internal carotid arteries and M1 segment of right
middle cerebral artery (Figure 3B). He received surgery for
left distal femur fracture and laparotomy for intestinal
obstruction at the ages of twelve and fourteen months,
respectively. Under the treatment, the patient showed
improved alertness, better response to external stimula-
tion, and darker and less brittle scalp hair. Social smile was
observed at the age of ten months. He is now sixteen
months old and still has hypotonia and head lag. Speech
delay was also noted. The seizure pattern has changed to
infantile spasms from the age of seven months. The anti-
convulsants used currently are levetiracetam, topiramate
and vigabatrin.3. Discussion
MD is a rare neurodegenerative disorder caused by muta-
tions in ATP7A gene (MIM# 300011), leading to malfunction
of copper-dependent enzymes. The incidence estimated
ranges from 1 in 50,000 to 1 in 300,000 live births.1,2 In Asia,
one survey in Japan calculated the incidence as 1 in
354,507 live births.3 Most patients are males for the X-
linked recessive inheritance, though some female patients
have been reported.4
The location of ATP7A gene is on the long arm of the X
chromosome between positions q13.2 and q13.3. It en-
codes a copper-transporting P-type ATPase. The 8.5 kbvo Point Mutation in a Young Infant with Severe Menkes Disease,
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Figure 2 Brain MRI. A, B: T2 FLAIR sequence revealed encephalomalacia in bilateral temporal and left frontal lobes. C: T2WI
sequence revealed symmetric faint hyperintense areas in bilateral head of caudate nucleus and putamen. D: T1 FLAIR sequence
revealed dysgenesis of the genu and anterior body of corpus callosum.
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To date, more than 270 different mutations have been
reported, and some of them are not disease-related.5
About one-third of cases arise from de novo mutations.6
However, the mutation types are not obviously corre-
lated to the clinical course. This patient had a c.3502 C>T
point mutation in exon 17, leading to an early stop codon
with truncated protein (p.Gln1168X). The location of
this mutation is on the nucleotide-binding domain
(N-domain) of ATP7A gene. Since N-domain is one of the
characteristics of P-type ATPases, this mutation interferes
with normal recognition and binding of copper for further
transport and translocation.5 Previous reports on Menkes
mutations on the related locations of exon 17 of ATP7A
gene all showed classic phenotype of this disease,
including missense mutations of c.3299 T>C (died at
4.5 years)7 and c.3353 G>A (died at 1.5 years),8 as
well as frameshift mutation of c.3492delT (died at 4
months).9
There were limited reports on Menkes mutations in the
Taiwanese population. Mak et al.10 reported two de novo
mutations in the Taiwanese Menkes patients: c.2519 C>T,
resulting in a nonsense mutation, and c.3681delC, resulting
in frameshift mutation. The former patient died at 17
months old from respiratory failure.Please cite this article in press as: Lin Y-J, et al., A Truncating De No
Pediatrics and Neonatology (2014), http://dx.doi.org/10.1016/j.pednOur patient had acute intestinal obstruction and
received emergent laparotomy at fourteen months old. The
intestine was obstructed by a subserosal hematoma, which
could have been caused by the abnormal connective tissue
and blood vessels in MD. Neuroimages showed the pro-
gressive change from encephalomalacia to brain atrophy,
which was suggestive of a neurodegenerative process as
reported.11
Three stages of epilepsy have been identified.6 The first
stage presents as focal seizures at 3 months old. Three to 8
months later, the intermediate stage appears, with infan-
tile spasms. The late stage, at the mean age of 20 to 25
months old, is characterized by multifocal seizures. Our
patient currently appears to be in the intermediate stage,
with presentations of infantile spasm.
The benefits of early diagnosis and treatment with
copper-histidine in neonatal period have been re-
ported,12,13 including reduced seizure frequency and
improved EEG pattern. Some patients had normal neuro-
development and brain myelination. The recommended
dosage of copper-histidine is 200e1000 mg/day, once per
day or 2e3 times per week.14 Despite better prognosis in
some series, copper-histidine is ineffective in some other
patients.15 Our patient did not receive the treatment in the
neonatal period. However, four months after the initialvo Point Mutation in a Young Infant with Severe Menkes Disease,
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Figure 3 Brain MRI. A: Brain atrophy. B: tortuosity of bilateral internal carotid arteries and M1 segment of right middle cerebral
artery.
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+ MODELtreatment, he was found to be more physically active and
to have more facial expression. After five months of
treatment, the frequency of seizures decreased. Long-term
follow-up is needed to assess the neurodevelopment in
motor and language areas.
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